HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)
China · Delayed Price · Currency is CNY 3.430
+0.070 (2.08%)
Feb 3, 2026, 3:04 PM CST
SHE:002437 Revenue
HARBIN GLORIA PHARMACEUTICALS Co., LTD had revenue of 565.50M CNY in the quarter ending September 30, 2025, a decrease of -11.11%. This brings the company's revenue in the last twelve months to 2.25B, down -7.54% year-over-year. In the year 2024, HARBIN GLORIA PHARMACEUTICALS Co., LTD had annual revenue of 2.44B, down -7.06%.
Revenue (ttm)
2.25B
Revenue Growth
-7.54%
P/S Ratio
3.41
Revenue / Employee
831.75K
Employees
2,703
Market Cap
7.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.44B | -185.31M | -7.06% |
| Dec 31, 2023 | 2.63B | -481.91M | -15.51% |
| Jan 1, 2023 | 3.11B | -37.37M | -1.19% |
| Jan 1, 2022 | 3.15B | 90.36M | 2.96% |
| Dec 31, 2020 | 3.05B | -2.00B | -39.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Northeast Pharmaceutical Group | 6.85B |
| Cisen Pharmaceutical | 3.56B |
| Hunan Jiudian Pharmaceutical | 3.05B |
| Shandong Wit Dyne Health | 2.36B |
| Guangxi Wuzhou Zhongheng Group | 2.29B |
| Sunflower Pharmaceutical Group Co.,Ltd | 2.09B |
| Jiuzhitang | 1.94B |
| Hunan Er-Kang Pharmaceutical | 1.29B |